Kymera
Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results
from the Phase 1 healthy volunteer study of KT-621, its first-in-class,
oral STAT6 degrader medicine.
The
findings significantly surpassed the company’s expectations,
demonstrating robust STAT6 degradation and a favorable safety profile,
thereby derisking the program, the company said in a press release.
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 208
Founded by Bruce Lee Booth and Nello Mainolfi in September 2015
Headquartered in Watertown, Massachusetts
IPO: Aug 21, 20
Kymera
Therapeutics (Nasdaq: KYMR) is a clinical-stage biotechnology company
pioneering the field of targeted protein degradation (TPD) to develop
medicines that address critical health problems and have the potential
to dramatically improve patients’ lives. Kymera is deploying TPD to
address disease targets and pathways inaccessible with conventional
therapeutics. Having advanced the first degrader into the clinic for
immunological diseases, Kymera is focused on delivering oral small
molecule degraders to provide a new generation of convenient, highly
effective therapies for patients with these conditions. Kymera is also
progressing degrader oncology programs that target undrugged or poorly
drugged proteins to create new ways to fight cancer.
